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Abstract The mechanisms underlying arachidonic acid (AA)
release by uterine stromal (UIII) cells were studied. Stimulation
of AA release by calcium ionophore and PMA are inhibited by
various PKC inhibitors and by calcium deprivation. These results
suggest the involvement of an AA-specific cPLA2 as the release
of docosahexaenoic acid (DHA) from prelabelled cells is much
lower than the release of AA. The results also show a more
original stimulation of AA and DHA release induced by PKC
inhibitors, which is insensitive to calcium deprivation. This
stimulation is not due to acyltransferase inhibition, suggesting
the participation of a Ca2+-independent PLA2 (iPLA2). How-
ever, iPLA2 activity measured in UIII cells is inhibited by the
specific iPLA2 inhibitor, BEL, and is not stimulated by PKC
inhibitors, in contrast with the AA and DHA release. It seems
therefore that this iPLA2 cannot be involved in this mechanism.
The participation of another iPLA2, BEL-insensitive, is dis-
cussed.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
A key regulatory event in most cell types is the mobilization
of esteri¢ed arachidonic acid (AA) from cellular stores. AA
and its oxygenated metabolites (eicosanoids) then induce bio-
chemical events which alter numerous cell functions. One of
the major mechanisms involved in AA mobilization is the
hydrolysis of membrane arachidonoyl-sn-2-phospholipids cat-
alyzed by phospholipase A2 [1,2]. We have established a uter-
ine stromal cell line, named UIII, from adult rat [3] whose
growth is regulated by polyunsaturated fatty acids (PUFA).
Arachidonic acid signi¢cantly increases UIII cell growth
whereas docosahexaenoic acid (DHA) at micromolar concen-
trations induces a dose-dependent inhibition of cell prolifera-
tion not related to the production of peroxidation products
[4]. A number of other fatty acids could not elicit these e¡ects
showing the speci¢city of AA and DHA. Moreover, the pro-
liferation e¡ect could be blocked in a dose-dependent and
reversible manner by inhibitors of phospholipase A2 but not
by inhibitors of eicosanoid synthesis [5], suggesting that the
polyunsaturated fatty acid was directly responsible for this
e¡ect. This conclusion is supported by the work of others
who have shown proliferation-dependent changes in release
of arachidonic acid from endothelial cells [6] and ¢broblasts
[7]. AA release from phospholipids decreased with con£uence,
and phospholipase A2 activity changed in concert with the
alteration of the release.
There is now increasing evidence that a cytoplasmic phos-
pholipase A2 (cPLA2), which speci¢cally catalyses the release
of AA from the sn-2 position of phosphoglycerides, could be
the main pathway of arachidonate mobilization in activated
cells [8^11]. Activation of the enzyme is thought to occur by
two mechanisms. One mechanism involves a Ca2-dependent
translocation of cPLA2 from the soluble to membrane frac-
tions of cells, allowing cPLA2 access to its substrate [12]. The
second involves phosphorylation of cPLA2, resulting in stim-
ulation of its intrinsic enzyme activity [13]. Mitogen-activated
protein kinases (MAPK) have been proposed as the enzymes
involved in cPLA2 phosphorylation and PKC-dependent and
PKC-independent mechanisms for the activation of MAPK,
and consequently of cPLA2, have been described [14].
In order to focus upon the role of PKC on the release of
AA, we have assessed the e¡ects of known inhibitors of pro-
tein kinases on the release of radioactive AA in prelabelled
cells stimulated with the Ca2-ionophore A23187, to mimic
the e¡ects of a Ca2-mobilizing ligand or with PMA, a direct
activator of PKC. The results show that the stimulation of
AA release by A23187 and PMA stimulation was inhibited by
PKC and tyrosine kinase inhibitors and by calcium depriva-
tion. The results also show a more original stimulation of AA
and DHA release induced by PKC inhibitors in resting cells,
which is insensitive to calcium deprivation. This result is in-
teresting as it involves a regulatory pathway di¡erent from the
stimulation of AA release by cPLA2. This pathway is not
regulated by acyltransferases as shown by the absence of e¡ect
of calphostin C on [3H]AA or [3H]DHA incorporation into
phospholipids. The involvement of Ca2-independent PLA2
(iPLA2) was also investigated. The iPLA2 activity measured
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in UIII cells was inhibited by BEL, a suicide inhibitor of the
best characterized iPLA2 [15^17], and was not stimulated by
PKC inhibitors, in contrast with AA and DHA release. More-
over, preincubation of cells with BEL did not impair the stim-
ulation of AA release induced by calphostin C, suggesting that
the BEL-sensitive iPLA2 is not involved in this releasing path-
way.
2. Material and methods
2.1. Chemicals
Tissue culture medium M199, L-glutamine, penicillin, streptomycin,
fetal calf serum (FCS) were obtained from GIBCO (Cergy-Pontoise,
France). [5,6,8,9,11,12,14,15-3H]arachidonic acid (210 Ci/mmol), [4,5-
3H]docosahexaenoic acid (58 Ci/mmol), L-K-dipalmitoyl-[2-palmitoyl-
1-14C]phosphatidylcholine (55.5 mCi/mmol) were obtained from New
England Nuclear (Boston, MA). Standard free fatty acids and phos-
pholipids, fatty acid-free bovine serum albumin (BSA) and calphostin
C were from Sigma (St. Louis, MO). Calcium ionophore A23187,
phorbol 12-myristate 13-acetate (PMA), H-7, H-89 and staurosporine
were from Calbiochem (La Jolla, CA). The Ca2-independent PLA2
inhibitor (E)-16-(bromomethylene)tetrahydro-3-(1 naphthalenyl)-2H-
pyran-2-one (bromoenollactone, BEL) was synthesized as described
previously by Daniels et al. [18]. All other chemicals were of analytical
grade.
2.2. Cell culture
For stock culture, UIII cells were grown in medium 199 supple-
mented with 10% FCS, 2 mM L-glutamine, 100 units/ml penicillin
and 100 Wg/ml streptomycin. They were incubated in 75 cm2 Falcon
plastic £asks in a 95% air-5% CO2 humidi¢ed atmosphere at 37‡C.
The medium was changed every 48 h. Con£uent cells were subcultured
by incubation with 0.25% trypsin, centrifuged and seeded at 1:2 ratio.
Cell viability, determined by the trypan blue exclusion method, was
consistently greater than 95%.
2.3. Incorporation and release of arachidonic and docosahexaenoic
acids
Con£uent cells from stock culture were trypsinized, resuspended
into medium 199 with 10% FCS and seeded at 1.5U105 cells/well in
12-well culture plates and incubated for 24 h. The medium was then
removed and cells were incubated for 8 h in medium 199 with 1 mg/ml
fatty acid-free BSA that contained 0.5 WCi/ml of [3H]AA or
[3H]DHA. The labelling medium was aspirated and cells were washed
twice with medium 199+0.1% BSA followed by another incubation
for 16 h at 37‡C in medium 199+10% FCS, without label. The me-
dium was then aspirated and cells were washed again three times with
medium 199+0.1% BSA and incubated for 5 to 60 min in 1 ml of the
same medium at 37‡C with or without agonists. The radioactivity
released in the medium was measured by scintillation spectrometry
and was normalized as the percentage of the total incorporated radio-
activity. Total radioactivity was de¢ned as the sum of the radioactiv-
ity released in the medium and the radioactivity remaining in cell
lipids.
Experiments were also performed to determine the distribution of
the label within lipid and phospholipid classes at the end of the label-
ling period. Total lipids from washed cells and from media were
extracted according to the procedure of Bligh and Dyer [19]. The
amount of radioactivity was determined by liquid scintillation spec-
trometry on an aliquot of the organic phase. The distribution of
radioactivity within lipid and phospholipid classes was determined
after TLC and HPLC separation as described previously [20]. Total
lipids were also submitted to transmethylation, the resulting fatty acid
methyl esters (FAMEs) were separated by reversed phase HPLC [20]
and their radioactivity was determined using a Radiomatic Flow One
L detector.
2.4. Ca2+-independent phospholipase A2 assay
UIII cells were adjusted to a concentration of 1.2U107 cells/ml with
homogenization bu¡er (10 mM HEPES, 1 mM EDTA, 1 mM DTT
and 0.34 M sucrose), brie£y sonicated and immediately centrifuged at
1000Ug, 4‡C for 5 min. The resulting low speed supernatant (LSS)
was used for iPLA2 assay, according to Ackermann et al. [21] with
minor modi¢cations. The standard assay contained 1.2 mM Triton X-
100, 120 WM dipalmitoyl phosphatidylcholine (DPPC), 5 mM EDTA,
100 mM HEPES (pH 7.5) and 0.8 mM ATP in a ¢nal volume of 500
Wl. The substrate was prepared by evaporating the required amounts
of dipalmitoyl-PC- and 1-palmitoyl-2-[1-14C]palmitoyl-sn-glycero-3-
phosphocholine (200 000 dpm per assay) to dryness under a stream
of N2. The dried phospholipids were resuspended with 450 Wl of assay
bu¡er. Mixed micelles were formed by a combination of heating
(above 40‡C), vortexing and water bath sonication until clari¢cation.
Assays were initiated by the enzyme addition to the substrate mix-
ture and were incubated at 40‡C for 60 min with agitation. The re-
action was stopped by the addition of 2 ml of chloroform-methanol
(2:1, v/v) containing 0.02% butylated hydroxy toluene (BHT) as an
antioxidant and 100 Wg of oleic acid as a carrier. The extraction of
lipids was completed by the addition of 0.2 ml of 2 mol/l KCl plus 0.5
mmol/l EDTA. After centrifugation (900Ug for 5 min), the chloro-
form layer was removed by aspiration. A second extraction with 1 ml
of chloroform was done and pooled chloroform extracts were evapo-
rated to dryness under vacuum. Lipid classes were separated using
anion exchange chromatography columns as described previously
[22]. The iPLA2 activity was determined from the radioactivity found
in the unesteri¢ed fatty acid fraction. iPLA2 activity values, measured
in the LSS of UIII cells homogenate, were normalized to the protein
content of the assay and expressed as pmol palmitic acid released
min31 mg31 protein.
3. Results and discussion
3.1. [3H]AA and [3H]DHA labelling and release from
phospholipids
TLC analysis of cellular lipids after labelling of the cells
showed that more than 97% of the label was associated with
phospholipids, only trace amounts were found in triglycerides
and free fatty acids. HPLC analysis of cellular phospholipids
demonstrated a distribution of the label, either [3H]AA or
[3H]DHA, very close to the distribution of the corresponding
endogenous fatty acid as measured by GLC analysis [20]. As
expected, the distribution of the label within phospholipid
classes was very di¡erent for [3H]AA (PE, 38.4 þ 2.0%; PC,
28.5 þ 1.8%; PI, 25.6 þ 1.3%; PS, 1.3 þ 0.5%) and [3H]DHA
(PE, 67.0 þ 2.3%; PC, 14.1 þ 1.0%; PS, 5.5 þ 0.4% and
PI9 0.2%).
TLC analysis of lipids from media obtained from control
and stimulated cells showed that more than 95% of the radio-
activity released during the experiment was recovered as free
fatty acids, and 1 to 3% were recovered as phospholipids. The
latter likely correspond to the very few cells that detach from
the monolayer. Only trace amounts of labelled triglycerides
and sterol esters were found. No oxygenated derivatives
from AA or DHA were observed in the medium. Reversed
phase HPLC analysis of FAMEs from media showed that the
radioactive fatty acid released was mainly AA (more than
90%) and its elongated derivative (22:4n36, 4 to 8%) when
cells were labelled with [3H]AA and exclusively DHA when
cells were labelled with [3H]DHA (not shown).
3.2. Regulation of AA release in resting and A23187-activated
cells
The incubation of cells with increasing concentrations of
A23187 (0.1^1 WM) resulted in a dose-dependent increase of
[3H]AA release (Fig. 1). Short term treatment of cells with
PMA alone, a direct activator of protein kinase C, did not
induce any AA release (Fig. 1, insert). However, pretreatment
with PMA (5 min) followed by A23187 resulted in a signi¢-
cantly larger increase in arachidonate release, compared to
A23187-treated cells (Fig. 1, insert). This priming e¡ect of
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PMA has been shown in a variety of cells [13,23] where phos-
phorylation of cPLA2 must be combined with a calcium-mo-
bilizing agonist to increase AA release. In other cell models,
PMA can induce an increase in phosphorylation and catalytic
activity of cPLA2 as well as arachidonic release without an
increase in intracellular calcium [24,25]. This suggests that
cell-speci¢c pathways for regulation of cPLA2 activation
and AA release may exist.
To determine the importance of phosphorylation in
A23187-induced AA release, the e¡ect of di¡erent protein
kinase inhibitors was examined. Pretreatment of UIII cells
with H-89, a potent and selective inhibitor of PKA, was with-
out e¡ect on both basal and A23187-induced arachidonate
release (Fig. 2). The tyrosine kinase inhibitor genistein has
no e¡ect on the basal release of [3H]AA but inhibited the
arachidonate release induced by A23187 by 53% (P6 0.01)
(Fig. 2). The protein kinase C inhibitors, H-7, staurosporine
and calphostin C, also inhibited the release of [3H]AA in cells
stimulated by A23187 (38%, P6 0.01, 52%, P6 0.01 and 65%,
P6 0.01, respectively) (Fig. 2b). They also completely blocked
the priming e¡ect of PMA on A23187-induced AA release
(not shown), as previously shown by Lin et al. [13] with stau-
rosporin in CHO cells. Surprisingly, these PKC inhibitors
signi¢cantly increased the release of [3H]AA in non-stimulated
cells by 63%, 45% and 112%, respectively (Fig. 2a). This un-
expected stimulation of basal AA release was dose-dependent
up to 250 nM when studied in response to calphostin C
(Fig. 3).
The di¡erences in the e¡ects of PKC inhibitors in resting
and stimulated UIII cells suggest that di¡erent pathways for
AA release may occur, depending on cell activity. In order to
test this hypothesis, we compared the e¡ect of calphostin C in
resting and A23187-activated cells labelled either with [3H]AA
or [3H]DHA, the latter being poorly released by cPLA2 com-
pared to AA [26]. We also tested the dependency of calphostin
C-induced fatty acid release on calcium. Results are summa-
rized in Fig. 4. Unstimulated cells, prelabelled with [3H]AA or
[3H]DHA, released similar amounts of these radioactive fatty
acids in the culture medium. Calphostin C increased the re-
lease of [3H]AA and [3H]DHA to the same extent (about 2-
fold). By contrast, A23187 increased much more the release of
[3H]AA (about 7-fold) than that of [3H]DHA (about 2-fold).
Moreover, the chelation of extracellular Ca2 by EGTA (3
mM), which prevents the in£ux of Ca2, had no e¡ect on
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Fig. 2. E¡ect of protein kinase inhibitors on the basal (a) or A23187-stimulated (b) release of [3H]AA from UIII cells. Cells labelled with
[3H]AA were preincubated for 45 min with or without (control) 1 WM H-89, 370 WM genistein, 200 WM H-7, 500 nM staurosporin, or 250 nM
calphostin C, washed and then incubated with medium only (a), or 0.5 WM A23187 for 15 min (b). [3H]AA released in the medium was meas-
ured. Data, expressed as the percentage of total radioactivity initially incorporated in cells, are means þ S.D. of three separate experiments.
*Signi¢cantly di¡erent (P6 0.01) from the corresponding control.
Fig. 1. Concentration-dependent release of [3H]arachidonic acid by
A23187-activated cells. Cells were labelled with [3H]arachidonic
acid, washed, and then incubated with the indicated concentration
of A23187 for 15 min. The [3H]AA released in the medium during
this period of time was counted. The data are presented as the per-
centage of the total 3H radioactivity initially incorporated in cells
and expressed as means þ S.D. of three separate experiments. Insert:
Cells labelled with [3H]AA were washed and then incubated with
medium only (control), 1 WM PMA for 15 min, 1 WM A23187 for
10 min, or 1 WM PMA for 5 min followed by 1 WM A23187 for 10
min (PMA/A23187). [3H]AA released in the medium was measured.
Results are means þ S.D. of three separate experiments.
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calphostin C-induced AA or DHA release whereas the stim-
ulatory e¡ect of A23187 was completely abolished. The same
results were observed when BAPTA (100 WM), an intracellular
Ca2 chelator, was used in addition with EGTA (not shown).
These data show that the regulation of arachidonate mobi-
lization within UIII cells could occur at least by two di¡erent
pathways. The stimulation of AA release by calcium iono-
phore and PMA, which is inhibited by various PKC and
tyrosine kinase inhibitors and calcium deprivation, is in ac-
cordance with previously reported data in other cell types
[9,13,23,27] where the regulation of cPLA2 in terms of phos-
phorylation and Ca2-dependent activation has been well
characterized [14,28]. The results suggest the involvement of
an AA-speci¢c cPLA2, as the release of DHA from prela-
belled cells was much lower than the release of AA. The
data also demonstrate a more original stimulation of basal
AA release induced by PKC inhibitors. A similar ¢nding
has been reported in human neutrophils [29] and more re-
cently in human platelets [30] where calphostin C, but not
staurosporin and H-7, also induced a direct release of AA.
This regulatory pathway is insensitive to calcium deprivation
and equally a¡ects DHA release, suggesting that it is di¡erent
from the stimulation of AA release by cPLA2. Moreover, the
absence of e¡ect of genistein, which strongly reduces the
A23187-induced AA release, and of H-89, suggests that this
pathway in not regulated by tyrosine kinases nor by cAMP.
3.3. Role of acyltransferases
Increase of AA release could result from the activation of a
Ca2-independent PLA2 or from the inhibition of acyltrans-
ferases. There have been several reports concerning the regu-
lation of acyl-CoA: lysophospholipid acyltransferase activity
by PKC. Treatment of macrophages and platelets with acti-
vators of PKC inhibits arachidonoyl CoA acyltransferase
which results in an increase in AA release and a decrease in
AA uptake by the cells [31,32]. In order to assess the role of
acyltransferases, we studied the incorporation of exogenous
[3H]AA and [3H]DHA into cellular phospholipids in the ab-
sence or presence of calphostin C. Merthiolate, a known in-
hibitor of acyltransferases [33] was used as control. Cells were
pretreated with 250 nM calphostin C or merthiolate (25^100
WM) and then incubated with [3H]AA or [3H]DHA for 30 min
in the presence of calphostin C or merthiolate. The radioac-
tivity incorporated in phospholipids was measured at the end
of the incubation as described in Section 2. Treatment of cells
with calphostin C did not induce any signi¢cant modi¢cation
of AA or DHA incorporation into phospholipids. Merthio-
late, as expected, led to a decrease in AA uptake by the cells
(19%, 33% and 44% with 25, 50 and 100 WM merthiolate after
30 min incubation, respectively), and to an increase by 2-fold,
4-fold and 10-fold in AA release from prelabelled cells when
incubated with 25, 50 and 100 WM merthiolate, respectively,
for 30 min. The lack of any inhibitory e¡ect of calphostin C,
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Fig. 4. E¡ect of extracellular Ca2 depletion on basal, calphostin C-, A23187- and calphostin C/A23187-induced [3H]AA or [3H]DHA release
from UIII cells. Cells labelled with [3H]AA or [3H]DHA were preincubated for 45 min with or without (untreated) 250 nM calphostin C,
washed and then incubated with medium only or with 0.5 WM A23187 for 15 min, in the absence (3EGTA) or presence (+EGTA) of 3 mM
EGTA. [3H]AA (a) or [3H]DHA (b) released in the medium was measured. Data are expressed as the percentage of the total radioactivity ini-
tially incorporated in cells, means þ S.D. of three independent measurements.
Fig. 3. Concentration-dependent release of [3H]AA by UIII cells pre-
treated with calphostin C. Cells labelled with [3H]AA were preincu-
bated for 45 min with or without (control) calphostin C at various
concentrations and washed before the [3H]AA released in the me-
dium for 15, 30 or 45 min was measured. Data are expressed as the
percentage of the total radioactivity initially incorporated in cells
and expressed as means þ S.D. of three independent measurements.
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compared to merthiolate, suggests that acyltransferases are
not involved in the stimulation of AA and DHA release by
PKC inhibitors.
3.4. Ca2+-independent PLA2 activity in UIII cells
We next tested the hypothesis that a Ca2-independent
phospholipase A2 was involved. Well characterized intracellu-
lar Ca2-independent PLA2 are limited to the 80-kDa Group
VI iPLA2 present in P388D1 macrophages [16] and CHO cells
[17], a 40-kDa iPLA2 present in myocardial tissue and pan-
creatic islets [15,34] and the 29-kDa Group VIII enzyme,
which is a PAF acetylhydrolase [35]. One common feature
of the 80- and the 40-kDa iPLA2 is their selective and irre-
versible inhibition by the mechanism-based inhibitor BEL
[15,36]. This compound exhibits an over 1000-fold selectivity
for the iPLA2 versus the Ca2-dependent PLA2 [15] and does
not a¡ect a number of enzyme activities directly involved in
AA metabolism such as arachidonoyl-CoA: lysophospholipid
acyltransferase and CoA-independent transacylase [37]. The
iPLA2 activity from low speed supernatant (LSS) of UIII cell
homogenate was assayed with 120 WM phospholipid substrate
alone (vesicles) or in the presence of increasing amounts of
Triton X-100 (mixed micelles). 1,2-dipalmitoyl-PC (DPPC)
was used as substrate and the assays were carried out in the
presence or absence of 0.8 mM ATP. A iPLA2 activity was
detected in the LSS. In the absence of added ATP, maximal
activity was observed at a Triton X-100 concentration of 1.2
mM and was about 4-fold greater than that observed with
vesicles. Addition of 0.8 mM ATP resulted in an additional
increase of enzyme activity, about 3-fold in the absence of
Triton X-100 and about 2-fold in the presence of 1.2 mM
Triton X-100. Thus, maximal enzyme activity was observed
with the combination of 1.2 mM Triton X-100 and 0.8 mM
ATP and was roughly 9-fold greater than the activity ob-
served with vesicles of DPPC (35.8 þ 5.2 pmol/min/mg protein
and 4.3 þ 0.3 pmol/min/mg protein, respectively).
The involvement of a iPLA2 in agonist-induced AA release
has been suggested in di¡erent cells [38,39], based on BEL
inhibition of AA release. In macrophages however, BEL has
been shown to increase AA release [36]. The e¡ect of BEL on
iPLA2 activity in UIII cells is shown in Fig. 5. Preincubation
of cells for 30 min with increasing amounts of BEL resulted in
a dose-dependent inhibition of enzyme activity with an appar-
ent IC50 of about 7 WM (Fig. 5a). However, this inhibitory
e¡ect was not correlated with a dose-dependent inhibition of
AA or DHA release (Fig. 5b and c). Only a small decrease of
AA release was seen with 10 WM BEL, but a higher concen-
tration produced no e¡ect. The lack of a marked inhibitory
e¡ect of BEL on AA and DHA release indicates that the
BEL-sensitive iPLA2 does not signi¢cantly contribute to this
release in UIII cells. When cells were preincubated with cal-
phostin C no signi¢cant change in this enzyme activity was
observed (not shown), in contrast with AA release. Moreover,
when cells were preincubated with 50 WM BEL and 250 nM
calphostin C, the enzyme activity was reduced by about 90%
as in cells treated with BEL alone, but the basal release of AA
was stimulated to the same extent as in cells treated with
calphostin C alone (not shown).
The absence of correlation between iPLA2 inhibition and
fatty acid release together with the fact that the stimulation of
basal AA release by calphostin C persists in cells pretreated
with BEL suggest another releasing pathway. Another PLA2,
Ca2-independent but BEL-insensitive, might be involved.
Horrocks and colleagues [40,41] have identi¢ed in bovine
brain two iPLA2 with molecular masses of 110 and 39 kDa
that appeared to di¡er from myocardial and macrophage en-
zymes. The 39 kDa PLA2 selectively acts on 1-alk-1P-enyl-2-
acyl-sn-glycero-3-phosphoethanolamine (ethanolamine plas-
malogens) ; it is strongly inhibited by glycosaminoglycans
but is insensitive to BEL. A uterine enzyme with similar prop-
erties could be a good candidate since, in UIII cells, DHA is
mainly incorporated in ethanolamine plasmalogens [20], and
its release (Fig. 4b) is stimulated by the PKC inhibitor cal-
phostin C in the absence of calcium.
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Fig. 5. E¡ect of BEL on the Ca2-independent PLA2 activity (a) and on the basal release of [3H]AA or [3H]DHA (b, c). UIII cells were prein-
cubated with the indicated concentrations of BEL for 30 min (a). Then enzyme activity was measured as described in Section 2 and expressed
as the percent of control (enzyme activity in untreated cells, means þ S.D. of three independent measurements). Cells labelled with [3H]AA or
[3H]DHA were preincubated for 30 min with BEL at various concentrations and washed before [3H]AA (b) or [3H]DHA (c). The release in the
medium for 15 min was measured in the presence of 3 mM EGTA and 100 WM BAPTA. Data, expressed as the percentage of the total radio-
activity initially incorporated in cells, are means þ S.D. of three independent measurements. *Signi¢cantly di¡erent (P6 0.01) from the control.
H. Birbes et al./FEBS Letters 432 (1998) 219^224 223
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